Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) saw an upside of 1.01% to close Monday at $101.14 after adding $1.01 on the day. The 5-day average trading volume is 1,696,860 shares of the company’s common stock. It has gained $101.31 in the past week and touched a new high 3 times within the past 5 days. An average of 1,760,630 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,631,090.
HZNP’s 1-month performance is -1.52% or -$1.56 on its low of $98.80 reached on 08/03/23. The company’s shares have touched a 52-week low of $57.84 and high of $113.83, with the stock’s rally to the 52-week high happening on 01/03/23. YTD, HZNP has lost -11.12% or -$12.66 and has reached a new high 1 time. However, the current price is down -11.15% from the 52-week high price.
Insider Transactions
HZNP stock investors last saw insider trading activity on Jan 17.Pasternak Andy (EVP, Chief Strategy Officer) most recently sold 27,129 shares at $113.03 per share on Jan 17. This transaction cost the insider $3,066,323. EVP, Chief Financial Officer, Cox Aaron, sold 36,148 shares at a price of $113.17 on Jan 13. Then, on Jan 11, EVP and Chief Medical Officer SHERMAN JEFFREY W sold 3,368 shares at a price of $113.10 per share. This transaction amounted to $380,921.
Valuation Metrics
HZNP stock has a beta of 1.06. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 6.40 while the price-to-book (PB) in the most recent quarter is 4.53, with the price to cash flow ratio at 21.71.
Horizon Therapeutics Public Limited Company’s quick ratio for the period ended March 30 was 3.90, with the current ratio over the same period at 4.10. As well, the company’s long term debt to equity for the quarter ending March 30 was 0.50, while the total debt to equity was 0.50. In terms of profitability, the gross margin trailing 12 months is 74.40%. The trailing 12-month EBITDA margin is 30.09% while for the period ending March 30, Horizon Therapeutics Public Limited Company’s operating margin was 12.80%. The firm’s gross profit as reported stood at $2.71 billion against revenue of $3.63 billion.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -273.56% to $54.68 million, while revenue of $120.41 million was -120.21% off the previous quarter. Analysts expected HZNP to announce $1.12 per share in earnings in its latest quarter, but it posted $0.83, representing a -25.90% surprise. EBITDA for the quarter stood at more than $132.32 million. HZNP stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 3.9 billion, with total debt at $2.68 billion. Shareholders hold equity totaling $228.62 million.
Let’s look briefly at Horizon Therapeutics Public Limited Company (HZNP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 54.58% to suggest the stock is trending Neutral, with historical volatility in this time period at 9.84%.
The stock’s 5-day moving average is $99.79, reflecting a +0.87% or $0.87 change from its current price. HZNP is currently trading -1.45% above its 20-day SMA, -7.80% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +1.65% and SMA200 by+58.80%.
Stochastic %K and %D was 23.13% and 12.16% and the average true range (ATR) pointed at 1.03. The RSI (14) points at 49.57%, while the 14-day stochastic is at 42.24% with the period’s ATR at 1.03. The stock’s 9-day MACD Oscillator is pointing at 0.23 and -0.38 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Horizon Therapeutics Public Limited Company (NASDAQ: HZNP), H.C. Wainwright launched coverage with a Neutral rating. Analysts offering their rating for HZNP stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate HZNP as a “sell,”, while 6 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is HZNP’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $116.50 and a high of $116.50, with their median price target at $116.50. Looking at these predictions, the average price target given by analysts is for Horizon Therapeutics Public Limited Company (HZNP) stock is $116.50.
